Ecole Centrale Paris / Université Paris IX Dauphine / CNAM / Mini MBA McKinsey

Mini MBA McKinsey

Ecole centrale de Paris / Centrale Paris

Université Paris Dauphine

Conservatoire National des Arts et Métiers / CNAM

Entrepreneur • CEO • Pharma-Biotech-Digital • Keynote Speaker • Senior Expert • Smart Data • AI • R&D Life Sciences

Paris, Île-de-France, France

Bio-Modeling Systems is the world’s first Mechanisms-Based Medicine company that created  CADI Discovery the first Computer Augmented Intelligence operational Plaform in Life sciences. It changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™ Discovery models.

We propose to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses.

Created in 2004, profitable since 2006, thanks to our recurrent clients, we confirmed with our partners CADI™ Discovery capability to generate outstanding value through:
- Strong & long term strategic R&D collaborations (>100 people collaborating).
- Dual business model : Contractual or Collaborative R&D programs.
- External valorization of our collaborative R&D programs through out-licensing or spin-off.
- Outstanding internal pipeline of programs ready for collaborations, and
- Already 1 therapeutic spin-off, 1 exclusive out-license, 14 CADI™ successes independently validated by our clients/partners, 4 issued patents and 10 publications.

You have a question, we may have the ability to generate the answer through one of our 6 BMSystems’ solutions to critical & high impact issues.
- GO-NO GO decision before product acquisition or for portfolio risk analysis.
- GO-NO GO decision before next development phase.
- R&D program Rescue for a program facing critical issues during its lifetime.
- External R&D “B plan” program when the “A plan” cannot be rescued.
- Exploratory Discovery program to discover novel causal mechanism concept
- Novel Hypotheses discovery and novel therapeutic and/or diagnostic solutions.

Bio-Modeling Systems

Co-founder, CEO, &  EVP R&D IT and Systems

The 1st Pharmaceutical Alliance in Europe.
The network of excellence and innovation of the health sector Made in France.
POLEPHARMA stimulates industrial and economic development of actors of the French
first pharmaceutical sector with actions that promote competitiveness, innovation and
attractiveness to the advantage of the job market.

POLEPHARMA

Board Member

Bolero créé par Caroline Faillet devient Opinion Act: Le nom Opinion Act est un signal, celui de la prise de conscience que l’insurrection numérique a eu lieu.
Nouvelle étape stratégique pour une collaboration Santé / Pharma inititée en 2017
Paris, le 28 mai 2019 – Bolero, dirigé par Caroline Faillet, est le leader de la digital-intelligence. Fort de nombreuses références dans le secteur (Roche, Sanofi, Mylan, Merck, MSD, Vetoquinol…), Bolero a décidé en 2019 de renforcer son offre unique Pharma/Santé pour accompagner les entreprises pharmaceutiques dans la construction de leur leadership sur le digital.
Pour renforcer leurs offres et accélérer la convergence recherche clinique et données de vraie vie, Bolero bénéficiera de l’expérience de Manuel Gea en tant qu’ancien patron de Business-Unit chez Boehringer Ingelheim, ancien DG Europe d’une biopharma américaine, créateur de la practice Santé chez McKinsey, marketing manager chez Colgate-Palmolive ainsi qu’entrepreneur dans les données de santé avec Bio Modeling Systems.

Opinion Act

Advisory Board Member

MANAGEMENT et DIGITAL sont ils optimums  dans votre organisation ? Ce diagnostic, en accès libre sur <a href="http://lediag.net">lediag.net</a> , vous aide à faire le point sur 5 grandes dimensions : Energie, Talents, Confiance, Avenir et Digital.

Plusieurs dizaines d'experts et dirigeants ont participé à la mise au point de ce nouvel outil d'évaluation qui prend enfin en compte les attentes des générations "millénium"​ et l'importance du digital dans l'efficacité du management.

Le réseau de partenaires BtoB est ouvert aux professionnels qui souhaitent utiliser cet outil chez leurs propres clients.

Diagnostic Management et Digital

Co-founder & VP Strategy

Bolero a développé un pôle pharma afin de répondre à ces enjeux complexes avec une offre unique dédiée à la construction d’un leadership sur le digital :

Conseil pour le développement de plateformes web puissantes sur les aires thérapeutiques
Conseil pour la mise en place de stratégies d’information patients et professionnels de santé sur les réseaux sociaux qui respectent la charte ANSM
Audit des services digitaux pour rationaliser ou améliorer la performance et protéger la réputation
Etudes des parcours digitaux patients et professionnels de santé
Cartographies de communautés patients et professionnels de santé pour améliorer la connaissance client et utilisateur
Veille d’opinion, veille de réputation, veille de crise, en intégrant la pharmacovigilance digitale.
Veille marché, veille concurrentielle, veille insights pour imaginer de futures innovations de services associés aux médicaments.
Pour renforcer l’expertise de son pôle pharma présent à Paris et à Lyon, Bolero s’est doté d’un advisory board d’anciens du secteur pharmaceutique.

Pharma & healthcare Expert

Founded in July 2010, the Innovative Company Biophys-Solutions is expert in counseling, proposes and implements customized ecological-technological solutions.

Biophys-Solutions Company operates and provides customized physical environmental technology for the formulation of innovative products in areas as diverse as agronomic, food science, research and analysis, cosmetics, nutraceutical, parapharmaceutical and water treatment.

Flexibility, competence and responsiveness of biophysical solutions are the key tools used to ensure a quality service.

BioPhys-Solutions

Advisory Board Member & shareholder

The goal of the digital health commission is to encourage collaborative technology, patients' experience improvement and digital health projects in the Ile de France region. It is composed of various actors of the health ecosystem of different sizes and horizons as well as institutional  and medical research. We wish to encourage and support structuring projects that improve patient experience using novel technologies, digital tools.

Medicen Paris Region

Co-founder of the Digital Health Commission

France’s independent multidisciplinary biotechnology think-tank
-  Building on France’s largest multidisciplinary life sciences network, Adebiotech’s goal is to promote responsible disruptive innovation and its uses.
-  Adebiotech brings together experts from industry (SMEs and large companies) and academia,
furthermore governing bodies contribute to its activities.
-  Adebiotech works across the entire biotechnology spectrum: human and animal health, environment, energy, food/feed, cosmetics, industrial processes…

Download the presentation to discover the missions, the <a href="http://publications,www.adebiotech.org">publications,www.adebiotech.org</a>.

Represented Members & Partners
Industrial
Air Liquide, ARD, Axialys Innovations, Bio-Modeling Systems, Bpifrance, Biocitech, Cargill, Cell & Co Biorepository, CSTB, Eco-Solution, EMERTEC Gestion, Fermentalg, Genoscreen, Genostar, Ingredia, INVIVO NSA, Kallistem, Lesaffre International, LFB Biotechnologies, Oroxcell,
Pall Life Sciences, Pharma Biot’Expert, Pherecydes-Pharma, Physiostism, PROCIDYS, Profilomic, RD-Biotech, Roquette Frères, Sanofi, Scientis, Soliance, Springwave, Swissaustral Biotech, Takara Bio Europe-Clontech, Toulouse White Biotechnology, Veolia, WATCHFROG, Ynsect …

Academia
BRGM, CBSO, CEA DSV, CNRS-DIRE, CNRS-ISBG, ICBMS, IFREMER, INERIS, INRA, Institut Pasteur Paris, INSA Toulouse, Universités (Brest,
Clermont-Ferrand, Corte, La Rochelle, Lille, Lyon, Paris, Rennes)…
Institutional, Clusters, Partner associations
Ministries involved in Biotechnology (Agriculture, Environment, Industry, Research); Clusters focussed on Health, Agri-business and marine biology, ACCINOV, national organisations (ANR), regional bodies (Biopôle Clermont-Limagne, CBB Développement, Conseil général Seine-Saint-Denis, Critt Santé-Bretagne), Clusters (Blue Cluster Algasud), trade associations (AFSSI, FIMEA, Leem, UIC), schools (AFPA, Sup'Biotech, ESIEE, ISFBM, LISBP-INSA),  (AgroParisTech, Centrale Santé, RNB, SFBBM, SFM, SFGP) …
<a href="http://www.adebiotech.org">www.adebiotech.org</a>
Disruptive Innovation

Adebiotech

Chairman

The clusters Cap Digital Paris-Region, Medicen Paris Region and Systematic Paris-Region launched a unique initiative to combine their skills and their ecosystems within the ICT for Health Paris Region Committee, covering markets of the whole e-health value chain

PERSONAL OBJECTIVE FOR THIS NOVEL ORGANIZATION:
Contribute to create a novel continuum between e-R&D and e-Health to enlarge and strengthen the translational medicine paradigm and extract the maximum pertinent medical meanings and value from scientific, medical, health, patients smart data.
We must not forget that the objective remains improving or providing a better life to  patients.

-  ASSETS
60 members: 40 small/medium companies, 2 major groups, 18 academic bodies,
18 accredited and funded projects,
A dynamic inter-cluster action in Paris Region,
Emergence at the technological, economic and industrial levels,
Addressing the challenges of personalised medicine.

-  TECHNOLOGICAL CHALLENGES
Predictive (bio) markers,
Development and miniaturization of sensitive and functionalized biosensors, development of algorithms translating signals into relevant medical information,
Smart devices and smart data,
Data security.

-  NON-TECHNOLOGICAL CHALLENGES
Fostering the emergence of sustainable economic models,
Stimulating the emergence of new forms of public procurement,
Measuring the impact of technologies and solutions on healthcare organization,
Anticipating the socio-cultural acceptability and adoption of technologies by users..

Founding member, Representative of Medicen Cluster Executive Board

Founded in 2005, the Medicen Paris Region global competitiveness cluster aims to position the Paris Region as a European industrial leader in diagnostic and therapeutic innovation and leading-edge health technologies, thus enabling it to become one of the global centres for translational medicine.
Medicen Paris Region’s partnership approach is based on the concept of economic value creation in the Paris Region stimulated by innovation, which forms the very basis of the creation of competitiveness clusters and sets three main priorities:

developing growth and employment in profitable markets in a successful dynamic relationship between YICs/SMEs, large firms and academic laboratories, clinical centres and educational establishments, promoting transfer of innovative technologies;

Contribute to:
-  The SME programs (relation with big Pharma)
-  Translational medicine new concepts (The Mechanisms-Based Medicine concept invented by BMsystems)
-  Digital strategy (create the link between e R&D and e Health
-  Develop disruptive innovation

Interested in french
Français
la médecine translationnelle, la médecine basée sur les mécanismes, la santé numérique, les biotechnologies, les nanotechnologies, l'industrie pharmaceutique, biopharmaceutique, les neurosciences, l'innovation de rupture, la biologie intégrative, la biologie des systèmes, technologies vertes, la modélisation non mathématique, énergie verte, le développement des médicaments, la recherche, le développement, l'informatique, l'intégration, la recherche opérationnelle, phage, décisionnel, Big Data, Cloud, Collaboration, systèmes embarqués, la mobilité, la sécurité, nouvelle recherche exploratoire, modélisation non conventionnelle, la psychiatrie, la fibromyalgie, la douleur, alzheimer, parkinson, la dermatologie, la cosmétique, la chimie.CEO, Président, chairman

Founding & Executive board member Administrator

Centrale-Santé:
The Professional Healthcare and biotech Think Tank
Professional Group Centrale Alumni Association

Centrale-Santé at a glance
-  The open “Professional group” of the Centrale Alumni Association (19 000 members, established in 1862, and declared of public interest in 1867).
-  First open and independent « Think Tank » in France established in 1996 offering an original associative answer to the 21st century innovation challenges in the healthcare field.
-  A 2 500 members network, with only 30% Centrale Alumni, gathering all the competencies, and expertises in the Technology and biotech universe. A distribution list of 5 000 people who are
linked to us and are informed of our work and programs.
-  The promoter of the opening and industrialization of the healthcare and biotechnology sector through its proposals and projects
-  The promoter of the Healthcare and Biotech Educational Center at Ecole Centrale Paris.
-  An open-minded network interconnected with the major actors of the sector.
-  An access gate to international networks through Alliances

Centrale-Santé: the integrated approach of healthcare issues
Three complementary approaches
-  Healthcare engineering : the pivot concept of Centrale-Santé.
Create and adapt engineering and project management concepts to
new healthcare organizations (networks and activity centers).
Transfer of engineering approaches to improve healthcare quality in a
difficult economic and social context.
-  Biotechnologies and Biomedical Technologies : From market
expectations to industrialization. Identify, develop, and transfer
technology and applications that will have to be adapted to the
medical field and financed.
-  Health-Environment : favoring Prevention and Hygiene and
Security, often left aside. Identify and measure the impact of the
environment on people's health and well-being.
-  Disruptive innovation

Centrale Sante

Co-founder, Chairman, Excecutive Vice-President innovation program

FORMITEL supports strategic consideration,  supplying our clients with interactive tools and sharing our dynamic methods of working group facilitation. Created by the founder of Centrale-Ethique for Centrale Paris Almuni Association
Diag26000
<a href="http://LeDiag.net">LeDiag.net</a>

- ICT innovation, #collaborative intelligence, Human Ressources, #Algorithms,

FORMITEL

Co-founder & Board Member

Manuel Gea est un ancien patron de Business-Unit chez Boehringer Ingelheim, ancien DG Europe d’une biopharma américaine, créateur de la practice Santé chez McKinsey, marketing manager chez Colgate-Palmolive ainsi qu’entrepreneur dans les données de santé avec Bio Modeling Systems.
Manuel Gea est également très impliqué dans les organisations professionnelles en tant que président de Centrale Santé, président d’Adebiotech, co-fondateur de la commission Digital Health de Medicen et administrateur de Polepharma, le 1er cluster Pharma d’Europe. En mai 2019, il rejoint en tant que qu’expert santé-pharma le pôle Santé-Pharma de la société Adevea Consulting qui est une agence conseil spécialisée en stratégie de marque employeur et développement du capital humain.

Adevea

Healthcare & Pharma Expert

the MEDEF life sciences and healthcare committee.
The Mouvement des Entreprises de France or MEDEF (in English: "Movement of the French Enterprises") is the largest union of employers in France
It has more than 700,000 member firms, 90% are from SME, with fewer than 50 employees. MEDEF is engaged in lobbying all decision-makers at the local, regional, national and European levels.
Every year, MEDEF International organises a number of delegations of French business leaders with concrete projects to targeted countries, especially developing countries.
MEDEF states that they endorse “sustainable development”, raising companies’ awareness to the fact that protection of the planet may also be numbered among their competitive advantages


Key words
mobile, santé, connecté, assurance, mutuelle, sciences de la vie, entreprise,CEO, disruptive  innovation

MEDEF

Co-founder Life Science & healthcare Committee

BMsystems' first operational and funded spin-off based on three proprietary patents (TAPE, AB-ACCUS, RIPh) in the field of infectious diseases (biosecurity)
Pherecydes Pharma is developing bacteriophages (phages) to rapidly detect and/or kill a large range of bio threats, including antibiotic resistant, emergent or previously uncharacterized bacteria, as well as nosocomial infections to treat people and/or environments.
Disruptive innovation. Digital biology discovery outputs

Pherecydes Pharma owns proprietary methods for accelerated targeted protein evolution, to built large phage banks or to engineer phages into targetable nano devices.

visit <a href="http://www.pherecydes-pharma.com">www.pherecydes-pharma.com</a>

Pherecydes-Pharma

Co-founder & President of the Advisory board

BMsystems' first operational and funded spin-off based on three proprietary patents (TAPE, AB-ACCUS, RIPh) in the field of infectious diseases (biosecurity)
Pherecydes Pharma is developing bacteriophages (phages) to rapidly detect and/or kill a large range of bio threats, including antibiotic resistant, emergent or previously uncharacterized bacteria, as well as nosocomial infections to treat people and/or environments.

Pherecydes Pharma owns proprietary methods for accelerated targeted protein evolution, to built large phage banks or to engineer phages into targetable nano devices.
Disruptive innovation. Digital biology discovery outputs

visit <a href="http://www.pherecydes-pharma.com">www.pherecydes-pharma.com</a>

Co-founder & Member of the Advisory board

Leading independent scientific Biotech Think Tank focused on the creation of synergies between all applications of biotech technologies
Main domains of interest:
- Medical biotech
- Industrial biotech
- Energy biotech

Interested in french
Français
la médecine translationnelle, la médecine basée sur les mécanismes, la santé numérique, les biotechnologies, les nanotechnologies, l'industrie pharmaceutique, biopharmaceutique, les neurosciences, l'innovation de rupture, la biologie intégrative, la biologie des systèmes, technologies vertes, la modélisation non mathématique, énergie verte, le développement des médicaments, la recherche, le développement, l'informatique, l'intégration, la recherche opérationnelle, phage, décisionnel, Big Data, Cloud, Collaboration, systèmes embarqués, la mobilité, la sécurité, nouvelle recherche exploratoire, modélisation non conventionnelle, la psychiatrie, la fibromyalgie, la douleur, alzheimer, parkinson, la dermatologie, la cosmétique, la chimie,

Vice-President

The French Pharma Association
The French Pharmaceutical  and biotech Companies’ Association
Promote collaborations between Pharma companies and biotech companies and academic research.
Define and promote best practices to create the best environment for innovation in the healthcare sector.
Interested in french
Français
la médecine translationnelle, la médecine basée sur les mécanismes, la santé numérique, les biotechnologies, les nanotechnologies, l'industrie pharmaceutique, biopharmaceutique, les neurosciences, l'innovation de rupture, la biologie intégrative, la biologie des systèmes, technologies vertes, la modélisation non mathématique, énergie verte, le développement des médicaments, la recherche, le développement, l'informatique, l'intégration, la recherche opérationnelle, phage, décisionnel, Big Data, Cloud, Collaboration, systèmes embarqués, la mobilité, la sécurité, nouvelle recherche exploratoire, modélisation non conventionnelle, la psychiatrie, la fibromyalgie, la douleur, alzheimer, parkinson, la dermatologie, la cosmétique, la chimie.

Leem

Vice-President Biotech Committee

Centrale Alumni Association (19 000 members, established in 1862, and declared of public interest in 1867
The École Centrale Paris was founded in 1829 to educate engineers capable of taking charge of the development of industrial applications arising from scientific discoveries within companies. Thus through its vocation, the École Centrale is the School for Companies. Strengthened and reinforced over the years, this intrinsic collaboration has become an everyday reality, and part of the life itself of the establishment.

<a href="http://www.centraliens.net">www.centraliens.net</a>

CentraleSupélec Alumni - Association

Private Public strategic studies and selection of candidates for the annual convention in order to propose recommendations.

CEPP - Centre d’Etudes secteur public-secteur prive

Member of the board,

L’Apm rassemble des dirigeants francophones d’entreprises (PME, PMI, ETI, Grands Groupes) et jeunes entrepreneurs. Ces dirigeants s’engagent à se perfectionner dans le but de faire progresser durablement leur entreprise.

Ce réseau international structuré en clubs est indépendant et apolitique. Il n’est pas un réseau d’affaires. Creuset d’idées et d’expériences managériales, l’Apm ne prend pas parti et ne se fait pas l’expression d’opinions sauf celui de l'international et de la francophonie !

7 200 dirigeants francophones - 360 clubs dans 26 pays - 350 experts.﻿ 20 000 dirigeants se sont perfectionnés au sein de l’Apm depuis 1987.

Les valeurs clés qui les fédèrent :
Ambition pour son entreprise et Humilité dans le comportement
Ouverture d’esprit
Confiance partagée et Respect des personnes
Exemplarité

Bénéficiant d’un fort développement international, l’Apm est présente dans 26 pays : Algérie, Allemagne, Angleterre, Autriche/Slovaquie, Belgique, Canada, Chine, Espagne, France, Hongrie, Ile Maurice, Italie, Luxembourg, Maroc, Monaco, Pologne, Portugal, République Tchèque, Roumanie, Russie, Singapour, Suède, Suisse, Thaïlande, Turquie, Vietnam. L’Apm est partenaire du réseau Entreprendre.
- dirigeant #entrepreneur #PME #PMI #ETI #innovation #management #formation

APM - Association Progrès du Management

Member

Co-founder & Chief Executive Officer of the European operations of Hemispherx Biopharma Inc..A biopharmaceutical company dedicated to orphan drugs business for immune systems disorders
Identification and support of patients Associations and potential medical centers to diagnose and treat the patients.
Compassionate drug use programs in Austria, Belgium

key words french
Président directeur général, maladie rares, biotechnologies, biopharmaceutique, diagnostique, association de patients, ATU, syndrome de fatigue chronique, fibromyalgie, médicaments orphelins,

Hemispherx Biopharma, Inc.

Co-founder & CEO Hemispherx EUROPE

A leading international german pharma company
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies..
The business unit for OTC, Semi-ethical & natural medicine portfolio including Pharmaton products and Ginseng Based Ginsana G115 treatments. European leader for natural medicine strategy including sourcing, regulations, clinical trials, MDs prescriptions,  development of new products and PR in collaboration with the coporate teams. Collaboration with Herbal medicine and traditional  medicine actors.


Key words Français
la médecine translationnelle, la médecine basée sur les mécanismes, la santé numérique, les biotechnologies, les nanotechnologies, l'industrie pharmaceutique, biopharmaceutique, les neurosciences, l'innovation de rupture, la biologie intégrative, la biologie des systèmes, technologies vertes, la modélisation non mathématique, énergie verte, le développement des médicaments, la recherche, le développement, l'informatique, l'intégration, la recherche opérationnelle, phage, décisionnel, Big Data, Cloud, Collaboration, systèmes embarqués, la mobilité, la sécurité, nouvelle recherche exploratoire, modélisation non conventionnelle, la psychiatrie, la fibromyalgie, la douleur, alzheimer, parkinson, la dermatologie, la cosmétique, la chimie, phytothérapie, vitamines et minéraux, médeicne tradionnelle

Boehringer Ingelheim

Managing Director, CEO Business unit France & European leader  for natural medicine strategy

Senior Consultant creator of the pharma practice of the company in France. In charge of consulting programs covering organisations issues and R&D pharma productivity and issues.
Various engagement (strategy, business development, research performance programs, due diligence, M&A, operational research.innovation strategies.
Various sectors: consumer goods, luxury, pharma, biotech, finance, manufacturing industry.

McKinsey & Company, Inc. is an American global management consulting firm headquartered in the U.S. The firm serves as an adviser to businesses, governments, and institutions. It was founded in 1926 in Chicago by James McKinsey as James O. McKinsey & Company and is now headquartered in New York City.

McKinsey & Company

Senior Consultant

A leading US consumer goods company
Develop Colgate Palmolive acquisition in bleach and refill packs in Asia.
Identified acquisition targets, proposed business development strategies and supported local teams to establish a worldwide business for Colgate Palmolive.

Colgate-Palmolive

International Business Manager

A leading US consumer goods company
New Products Marketing department France
Senior Product manager in charge of novel concepts for cosmetics lines, and the dishwashing gel Galaxy .
In addition to classical product manager job, Manuel Gea had a Technology focus: Introduction and development of simulation tools to generate better forecast
Disruptive innovation.

Product manager New Products department France

A leading US consumer goods company
Industrial engineer within the Technical department. Technology Focus:
Introduction and implementation of new computational languages of forth generation (Express) to
exploit logistics databases in order to modelize the logistics flows to design new warehouse systems.
in the major logistics program in Europe